Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

Description

This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.

Conditions

Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection

Study Overview

Study Details

Study overview

This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

Condition
Liver Transplant
Intervention / Treatment

-

Contacts and Locations

Chicago

Northwestern Memorial Hospital, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male and female recipients of all races, ≥18 years of age.
  • 2. Patients undergoing primary or subsequent living or deceased donor liver transplantation.
  • 3. Subject and/or guardian must be able to provide informed consent.
  • 4. Subject and/or guardian must be able to comply with the study protocol.
  • 1. Inability or unwillingness of a participant and/or guardian to provide informed consent.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Northwestern University,

Josh Levitsky, MD, PRINCIPAL_INVESTIGATOR, Northwestern University

Study Record Dates

2025-12